Progression-free survival (PFS)
Figure 1 · Panel Progression-free_survival_PFS_
Panel Progression-free_survival_PFS_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
N Peled, A Tufman, L V Sequist, G Pasello, Q Wang, L Antonuzzo, J González Larriba, S Medina Valdivieso, M Cobo Dols, M Milella, J Dudnik, P Martín-Martorell, I Barneto Aranda, D Huang, N V Palicio, A Scimone, E Bria, L Servidio, R Pimentel, A-A Ganiyu, J Zhao
ESMO Open 10(10) 105807
BACKGROUND: COMPEL (NCT04765059) was a global, randomized, double-blind study that evaluated osimertinib plus chemotherapy versus placebo plus chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) following non-central nervous system (CNS) progression on first-line osimertinib. PATIENTS AND METHODS: Patients were randomly assigned to receive osimertinib 80 mg, or placebo, once daily (o.d.) in combination with chemotherapy [cisplatin 75 mg/m2 or carboplatin area under the curve 5 plus pemetrexed 500 mg/m2 every 3 weeks (q3w) for four cycles], followed by osimertinib 80 mg, or placebo, o.d. in combination with maintenance pemetrexed (500 mg/m2 q3w) until progression. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included CNS PFS according to CNS metastases status at baseline and overall survival (OS). RESULTS: Ninety-eight patients were randomly assigned (49 per arm). Median PFS in all patients was 8.4 months [95% confidence interval (CI) 5.7-11.8 months] with osimertinib plus chemotherapy versus 4.4 months (95% CI 3.5-5.6 months) with placebo plus chemotherapy [hazard ratio (HR) 0.43, 95% CI 0.27-0.70]. CNS PFS was longer with osimertinib plus chemotherapy versus placebo plus chemotherapy (HR 0.56, 95% CI 0.27-1.13) in patients without baseline CNS metastases (n = 75). Median OS in all patients was 15.9 months (95% CI 12.4-20.8 months) with osimertinib plus chemotherapy versus 9.8 months (95% CI 8.4-17.2 months) with placebo plus chemotherapy (HR 0.71, 95% CI 0.42-1.23). Grade ≥3 adverse events occurred more frequently with osimertinib plus chemotherapy (63%) than placebo plus chemotherapy (46%). CONCLUSIONS: In patients with non-CNS progression on first-line osimertinib, osimertinib plus chemotherapy was associated with improved PFS and longer OS compared with placebo plus chemotherapy. These findings support osimertinib as a backbone treatment for EGFR-mutated advanced NSCLC through lines of therapy.
2 个 Figure · 3 个 KM 面板
Figure 1 Kaplan–Meier curve of progression-free survival (PFS) (full analysis set). Data cut-off: 28 October 2024. The crosses indicate censored observations. Progression events that did not occur within two missed visits of the last evaluable assessment were censored. The hazard ratio (HR) and confidence interval (CI) were calculated using a log-rank test.
Figure 1 · Panel Progression-free_survival_PFS_
Panel Progression-free_survival_PFS_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 Central nervous system (CNS) and non-CNS progression-free survival (PFS). Shown are Kaplan–Meier curves of (A) CNS PFS in patients without CNS metastases at baseline and (B) non-CNS PFS in all patients (full analysis set). Data cut-off: 28 October 2024. The crosses indicate censored observations. The hazard ratios (HRs) and confidence intervals (CIs) were calculated using a log-rank test.
这些图片未产生 KM 曲线结果,不在主页面重复展示。